2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
作者信息
Steffel Jan, Collins Ronan, Antz Matthias, Cornu Pieter, Desteghe Lien, Haeusler Karl Georg, Oldgren Jonas, Reinecke Holger, Roldan-Schilling Vanessa, Rowell Nigel, Sinnaeve Peter, Vanassche Thomas, Potpara Tatjana, Camm A John, Heidbüchel Hein
机构信息
Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich, Switzerland.
Age-Related Health Care, Tallaght University Hospital / Department of Gerontology Trinity College, Dublin, Ireland.
出版信息
Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065.
Abstract
摘要
相似文献
1
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065.
2
Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.
Future Cardiol. 2022 May;18(5):393-405. doi: 10.2217/fca-2021-0120. Epub 2022 Apr 1.
3
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Eur J Epidemiol. 2019 Feb;34(2):173-190. doi: 10.1007/s10654-018-0415-7. Epub 2018 Jun 8.
4
Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population.
Adv Ther. 2025 Mar;42(3):1462-1483. doi: 10.1007/s12325-024-03099-y. Epub 2025 Jan 30.
5
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118. Epub 2014 Feb 28.
6
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Stroke. 2018 Dec;49(12):2933-2944. doi: 10.1161/STROKEAHA.118.020232.
7
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Stroke. 2017 Sep;48(9):2494-2503. doi: 10.1161/STROKEAHA.117.017549. Epub 2017 Jul 17.
8
Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation.
Int J Cardiol. 2024 Jun 1;404:131894. doi: 10.1016/j.ijcard.2024.131894. Epub 2024 Mar 2.
9
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Medicine (Baltimore). 2020 Jul 2;99(27):e21025. doi: 10.1097/MD.0000000000021025.
10
Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study.
PLoS One. 2024 Nov 15;19(11):e0310322. doi: 10.1371/journal.pone.0310322. eCollection 2024.
引用本文的文献
1
Oral Anticoagulant Therapy in Patients with Atrial Fibrillation After Intracranial Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251368889. doi: 10.1177/10760296251368889. Epub 2025 Aug 21.
2
Measurement of plasma direct oral anticoagulants concentrations in real-world clinical and laboratory settings on a 24/7 basis: a 10-year experience.
J Thromb Thrombolysis. 2025 Aug 19. doi: 10.1007/s11239-025-03159-2.
3
Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications.
J Clin Med. 2025 Aug 7;14(15):5600. doi: 10.3390/jcm14155600.
4
Anti-Factor Xa Activity of Apixaban in Extremely Low Body Weight.
J Clin Med. 2025 Jul 24;14(15):5238. doi: 10.3390/jcm14155238.
5
Practical Comprehensive Approach to Current Atrial Fibrillation Challenges: Insights from an Expert Panel.
J Clin Med. 2025 Jul 22;14(15):5199. doi: 10.3390/jcm14155199.
6
Discrepancies in Recommendations on Pharmacokinetic Drug Interactions for Anticancer Medications and Direct Oral Anticoagulants (DOAC): A Comparative Analysis of Different Clinical Decision Support Systems and Sources.
Pharmaceuticals (Basel). 2025 Jul 16;18(7):1044. doi: 10.3390/ph18071044.
7
Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with liver disease: a systematic review and meta-analysis.
Front Pharmacol. 2025 Jul 14;16:1620394. doi: 10.3389/fphar.2025.1620394. eCollection 2025.
8
Identification of risk factors and development of a predictive model in patients using cefmetazole for international normalized ratio elevation.
PLoS One. 2025 Jul 28;20(7):e0322909. doi: 10.1371/journal.pone.0322909. eCollection 2025.
9
Serum Concentration of Apixaban in Relation to Renal Function in Older Hospitalized Patients.
Drugs Aging. 2025 Jul 24. doi: 10.1007/s40266-025-01232-2.
10
The Use of Direct Oral Anticoagulants (DOACs) in the Geriatric Population-How to Overcome the Challenges of Geriatric Syndromes.
J Clin Med. 2025 Jun 20;14(13):4396. doi: 10.3390/jcm14134396.
本文引用的文献
1
Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19.
J Arrhythm. 2020 Dec 11;37(1):231-237. doi: 10.1002/joa3.12458. eCollection 2021 Feb.
2
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
J Am Coll Cardiol. 2021 Mar 9;77(9):1197-1207. doi: 10.1016/j.jacc.2020.12.053.
3
Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis.
Thromb J. 2021 Feb 1;19(1):7. doi: 10.1186/s12959-021-00259-w.
4
Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis.
Heart. 2021 Mar;107(5):373-380. doi: 10.1136/heartjnl-2020-317901. Epub 2020 Dec 17.
5
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.
N Engl J Med. 2020 Nov 26;383(22):2117-2126. doi: 10.1056/NEJMoa2029603. Epub 2020 Nov 14.
6
Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study.
Am J Cardiovasc Drugs. 2021 May;21(3):363-371. doi: 10.1007/s40256-020-00449-3. Epub 2020 Nov 5.
7
Direct oral anticoagulant use in left ventricular thrombus.
Thromb J. 2020 Oct 29;18:29. doi: 10.1186/s12959-020-00242-x. eCollection 2020.
8
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR.
JACC Cardiovasc Interv. 2020 Nov 23;13(22):2587-2597. doi: 10.1016/j.jcin.2020.09.013. Epub 2020 Oct 28.
9
Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
Eur Heart J Cardiovasc Pharmacother. 2021 Apr 9;7(FI1):f50-f60. doi: 10.1093/ehjcvp/pvaa116.
10
Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures.
Eur Heart J Suppl. 2020 Sep 15;22(Suppl I):I32-I37. doi: 10.1093/eurheartj/suaa102. eCollection 2020 Sep.
Zotero 插件